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Abstract
 
The nature of peptides that positively select T cells in the thymus remains poorly defined. Here
we report an in vivo model to study the mechanisms of positive selection of CD4
 
 
 
 T cells. We
have restored positive selection of TCR transgenic CD4
 
 
 
 thymocytes, arrested at the
CD4
 
 
 
CD8
 
 
 
 stage, due to the lack of the endogenously selecting peptide(s), in mice deficient
for H2-M and invariant chain. A single injection of soluble agonist peptide(s) initiated positive
selection of CD4
 
 
 
 transgenic T cells that lasted for up to 14 days. Positively selected CD4
 
 
 
 T
cells repopulated peripheral lymphoid organs and could respond to the antigenic peptide. Fur-
thermore, coinjection of the antagonist peptide significantly inhibited agonist-driven positive
selection. Hence, contrary to the prevailing view, positive selection of CD4
 
 
 
 thymocytes can
be induced in vivo by agonist peptides and may be a result of accumulation of signals from
TCR engaged by different peptides bound to major histocompatibility complex class II mole-
cules. We have also identified a candidate natural agonist peptide that induces positive selection
of CD4
 
 
 
 TCR transgenic thymocytes.
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Introduction
 
T cell ontogeny is a multistep process resulting in the gen-
 
eration of mature peripheral CD4
 
 
 
 helper and CD8
 
 
 
 cyto-
toxic lymphocytes which recognize antigenic peptides pre-
sented by MHC class II or I proteins, respectively. During
development of the T cell lineage thymocytes are subject to
negative and positive selection processes that shape a reper-
toire of mature T cells that is tolerant to self-peptide–MHC
complexes and at the same time diversified enough to
mount an effective immune response (1, 2). Selection is
based on the interactions of immature CD4
 
 
 
CD8
 
 
 
 thy-
mocytes with peptide–MHC complexes on the surface of
thymic stromal cells and results in the three possible out-
comes. Thymocytes will die by apoptosis from neglect if
their TCRs do not interact with peptide–MHC strongly
enough to transduce a signal for positive selection (3). Thy-
mocytes, bearing receptors that interact strongly with self-
peptide–MHC, die from activation-induced apoptosis (4, 5).
Finally, thymocytes that interact weakly with peptide–MHC
undergo positive selection and survive to differentiate into
single positive CD4
 
 
 
 or CD8
 
 
 
 cells (6, 7). While the ability
of antigenic (i.e., agonistic) peptides to induce apoptosis of
CD4
 
 
 
CD8
 
 
 
 thymocytes in vivo is well established, the re-
lationship between antigenicity of peptides and their ability
to induce positive selection is controversial (8–10). Con-
flicting results concerning this issue have been obtained in a
variety of in vitro systems (11–14), but until now no suit-
able and relatively simple system to study the identity and
properties of peptides that mediate positive selection in vivo
has been available. Here we describe for the first time an in
vivo experimental model in which administration of soluble
peptide(s) results in positive selection of mature, peripheral
CD4
 
 
 
 T cells. The peptide ligands that initiate positive se-
lection of CD4
 
 
 
 T cells in this model have agonist activity,
whereas antagonist peptides only inhibited this process. Us-
ing protein sequence search algorithms we have identified
an endogenous agonist peptide which also induced positive
selection of transgenic T cells. This implies that natural pos-
itive selection of CD4
 
 
 
 thymocytes may be driven by high
not only low potency ligands.
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Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912-
2600. Phone: 706-721-8739; Fax: 706-721-8732; E-mail: ignatowi@
immagene.mcg.edu 
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Materials and Methods
 
Mice.
 
The TCR genes were cloned from T cell hybridoma
specific for analogues of the pigeon cytochrome C (PCC[43–
58])
 
*
 
 peptide and expressed in VA-hCD2 cassette (15–17). All
TCR transgenic mice (TCR
 
Tg
 
) were made by comicroinjection
of the respective TCR-
 
 
 
 and -
 
 
 
 constructs into fertilized eggs of
F1 (C57BL/6
 
 
 
CBA/Ca) mice. TCR
 
Tg
 
 mice were crossed to
C57BL6/TCR
 
  
 
 chain knockout mice (TCR-
 
 
 
 
 
; The Jackson
Laboratory) and to mice deficient in H2-M (H2-M
 
 
 
; provided
by E. Bikoff [Harvard University, Cambridge, MA] and R. Ger-
main [National Institutes of Health, Bethesda, MD]) and Ii (Ii
 
 
 
;
provided by L. van Kaer, Vanderbilt University, Nashville, TN)
to obtain TCR
 
Tg
 
TCR-
 
 
 
 
 
H2-M
 
 
 
Ii
 
 
 
.
 
Flow Cytometry Analysis.
 
Monoclonal antibodies specific for
CD4(RM4-5), CD8(53-6.7), V
 
 
 
8(F23.1), CD69(H1.2F3), CD44
(IM7), and CD62L(MEL-14) were purchased from BD PharMin-
gen and used according to the manufacturer’s recommendations.
Cells were analyzed using a FACSCalibur™ instrument (Becton
Dickinson) and CELLQuest™ software. For intracellular staining,
cells were first stained for CD4 and CD8, fixed in 2% paraformal-
dehyde, permeabilized in 0.1% Tween-20, and stained with anti–
bcl-2 antibody (BD PharMingen) according to the manufacturer’s
instruction.
 
Antigen Response and Antagonism Assays of TCR Transgenic
Cells.
 
Proliferation of lymph node cells isolated from TCR
 
Tg
 
TCR-
 
 
 
 
 
 and TCR
 
Tg
 
TCR-
 
 
 
 
 
H2-M
 
 
 
Ii
 
 
 
 mice injected with the
selecting peptide was measured in response to antigen. Response
of the TCR
 
Tg
 
TCR-
 
 
 
 
 
 lymph node cells to different agonist pep-
tides was measured by proliferation assay in a 96-well plate. 10
 
5
 
responder cells were stimulated with peptides presented by 5
 
  
 
10
 
5
 
 irradiated C57BL6 or H2-M
 
 
 
Ii
 
 
 
 splenocytes. Agonist and
control peptides were used at concentrations of 0.01, 0.1, 0.5, 1.0,
2.5, 5.0, 10.0, and 20.0 
 
 
 
M. After 3 d cells were pulsed with 1
 
 
 
Ci of [
 
3
 
H]thymidine added to each well and after 14–16 h thy-
midine incorporation was measured. The sequences of peptides
used were: PCC50V (AEGFSYTVANKNKGIT), PCC50L (AE-
GFSYTLANKNKGIT), PCC50V54A (AEGFSYTVANKAKGIT),
PCC46A49A50V54A (AEGASYAVANKAKGIT), PCC50F54A
(AEGFSYTFANKAKGIT), neutral ceramidase (AGFFQYTLY-
ILASEG), and IgGVH (NADFKTPATLTVDKA). All peptides
were synthesized by fluorenyl methoxycarbonyl chemistry and
purified by reversed-phase high performance liquid chromatogra-
phy. To compare the antigenic response of CD4
 
 
 
 TCR
 
Tg
 
 cells
lymph node cells were collected from TCR
 
Tg
 
TCR-
 
 
 
 
 
 and
TCR
 
Tg
 
TCR-
 
 
 
 
 
H2-M
 
 
 
Ii
 
 
 
 mice 2 wk after peptide injection.
Single cell suspensions were prepared and CD4
 
 
 
 cells were sorted
using magnetic beads coated with anti-CD4 antibodies (MACS
 
®
 
).
Purity of sorted cells exceeded 85%. 2
 
   
 
10
 
4
 
 of purified CD4
 
 
 
cells per well was used in proliferation assay. Cells were stimulated
with increasing concentrations of agonist peptides presented by
APCs from wild-type or H2-M
 
 
 
Ii
 
 
 
 mice. IgGVH-derived pep-
tide was used as a negative control. Proliferation was measured af-
ter 3 d by thymidine incorporation by pulsing cells with 1 
 
 
 
Ci of
[
 
3
 
H]thymidine for 16 h. Antagonism assay was done by prepulsing
5
 
   
 
10
 
5
 
 relevant APCs per well for 2 h with 5 
 
 
 
M of the anti-
genic peptide PCC50V54A, washing, and then exposing them to
varying concentrations of peptide analogues with 2
 
   
 
10
 
4
 
 purified
CD4
 
  
 
TCR
 
Tg
 
 lymphocytes as responder cells (18). For antago-
nism assays the percentage of proliferation inhibition was calcu-
 
lated as 100–100
 
* 
 
(thymidine incorporation in the presence of an-
tagonist/thymidine incorporation in the absence of antagonist;
reference 18).
 
Peptide Injections and Surgical Procedures.
 
TCR
 
Tg
 
TCR-
 
 
 
 
 
 and
TCR
 
Tg
 
TCR-
 
 
 
 
 
H2-M
 
 
 
Ii
 
 
 
 were injected intraperitoneally with
agonist and control peptides dissolved in PBS. Highly hydropho-
bic neutral ceramidase peptide was initially dissolved in DMSO
followed by dilution in PBS. After indicated time mice were
killed, thymus and lymph nodes were collected and single cell
suspensions were prepared. Pups were injected with 2 
 
 
 
g of pep-
tide subcutaneously 12–24 h after birth and thymi were trans-
planted into recipient mice 24 h after injection. 5–8-wk-old
TCR
 
Tg
 
TCR-
 
 
 
 
 
H2-M
 
 
 
Ii
 
 
 
 mice were used for thymectomy or
as thymic transplant recipients. Surgical procedures were per-
formed as described previously (19). Mice were handled accord-
ingly with the institutional guidance.
 
Protein Sequence Analysis.
 
Protein sequence database at the
National Center for Biotechnology Information was searched us-
ing BLAST, Psi-BLAST, and FASTA search algorithms with the
protein motif (AF)XX(AT)(VLFI)AXX(AN) as a query.
 
Results
 
Characterization of Peptide Agonists for the PCC-specific
Transgenic 
 
   
 
TCR.
 
To examine the role of peptides
during positive selection in vivo, we generated transgenic
mice expressing class II–restricted TCR specific for ana-
logues of a PCC(43–58) peptide presented by the A
 
b
 
 mol-
ecule (16). This receptor recognizes analogues of PCC(43–58)
in which aspartic acid in position 50 is replaced by amino
acids with neutral/hydrophobic (PCC50V, PCC50V54A,
PCC46A49A50V54A, PCC50L, PCC50F) side chains (Fig.
1). The TCR transgenic mice were backcrossed to
C57BL6 TCR-
 
 
 
 
 
 knockout mice so that almost all T
cells expressing transgenic TCR become CD4
 
 
 
 T cells
(Fig. 2, A and B). Initially we examined the capacity of
agonist peptides to induce negative selection of transgenic
 
*
 
Abbreviations used in this paper:
 
 FTOC, fetal thymic organ culture; PCC,
pigeon cytochrome C; TCR
 
Tg
 
, TCR transgenic mice.
Figure 1. Comparison of the agonist potency of the PCC50V,
PCC50L, PCC50V54A, PCC46A49A50V54A, and PCC50F54A pep-
tides. Total lymph node cells from TCRTgTCR-   mice were stimulated
with increasing concentrations of the agonist peptides. Unrelated peptide
IgGVH(59–74) was used as a control. Irradiated splenocytes from mice
expressing wild-type Ab were used as APCs. 
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T cells. We found that the efficiency of negative selection
correlated with the potency of individual agonist peptides.
However, an injection of 20
 
  
 
g of any tested agonist pep-
tide, in particular a moderate and a strong agonist
(PCC50V and PCC50V54A, respectively) did not induce
negative selection of transgenic thymocytes as assessed by
thymus cellularity, annexin V staining, and TUNNEL as-
say (Fig. 2, C and D, and data not shown). Strong agonists
PCC50L and PCC50V54A (Fig. 2 F) induced profound
negative selection when injected at 200 
 
 
 
g per mouse,
while moderate agonist PCC50V induced only marginal
deletion of CD4
 
 
 
CD8
 
 
 
 cells (Fig. 2 E).
 
Peptide Agonists Induce Positive Selection of Transgenic
CD4  T Cells. To examine the potential effect of agonist
peptides on in vivo positive selection of transgenic thy-
mocytes, we followed the ontogeny of these cells in a non-
selecting thymic environment where Ab molecules are de-
void of selecting peptides. For that purpose, we crossed
TCRTgTCR-   mice to Ii  and H2-M  mice to obtain
TCRTg on a triple knockout background (TCRTgTCR-
  H2-M Ii ). The development of the majority of CD4 
thymocytes is severely impaired in mice lacking H2-M and
Ii molecules, two molecular chaperones that participate in
peptide loading to MHC class II molecules (20–22). As ex-
pected, the thymic development of the transgenic T cells
was arrested at the stage of CD4 CD8  thymocytes and
only very few transgenic CD4  T cells were detected in
the periphery (Fig. 3 A). The lack of the natural positively
selecting Ab–peptide complex(es) resulted in a block in
thymocyte development and increased thymic cellularity in
TCRTgTCR-  H2-M Ii  mice. After these observations,
we attempted to restore positive selection in TCRTgTCR-
  H2-M Ii mice by providing exogenous peptides. A
number of irrelevant Ab-binding peptides (IgGVH[59–74],
OVA[323–339], E [52–68]), and analogues of PCC (50A,
50N, 50E, 52Q) without agonist properties had no effect
on thymic selection (data not shown). As shown in Fig. 3,
B–D intraperitoneal injection of a nondeleting dose of
PCC50V54A agonist peptide restored selection of CD4 
single positive thymocytes. Simultaneously, a number of
CD4 CD8  thymocytes upregulated CD69 and bcl-2 ex-
pression (Fig. 3, E and F). Positive selection of CD4  thy-
mocytes was sustained for 14 d after a single injection of
the selecting peptide ligand (Fig. 3 D). Contrary to the re-
cent report that agonist peptides induce selection of regu-
latory CD4 CD25 , cells in our model newly selected
CD4  thymocytes were CD25  (data not shown, and ref-
erence 23). The cellularity of the thymus and the number
of apoptotic cells detected by TUNNEL assay and annexin
V staining were the same in controls and in mice injected
with 20  g of agonist peptide PCC50V54A (data not shown).
Four other analogues of the PCC peptide, PCC50V,
PCC50L, PCC46A49A50V54A, and PCC50F54A, in-
jected at the same dose (20  g), also restored positive selec-
tion of transgenic thymocytes (data not shown). These re-
sults prove that positive selection of CD4  T cells can be
induced in vivo by different agonist ligands. An injection of
soluble agonist into TCRTgTCR-  →H2-M Ii  radia-
tion chimeras also resulted in positive selection of trans-
genic CD4  T cells, despite the expression of wild-type
Ab–peptide complexes on bone marrow–derived thymic
stromal cells (data not shown).
Positively Selected CD4  Thymocytes Repopulate Peripheral
Lymphoid Organs and Respond to Antigens. To determine
whether positively selected CD4  T cells leave the thymus
as functional, mature T cells, we analyzed lymph node cells
2 wk after peptide administration. As shown in Fig. 3 D,
TCRTgTCR-  H2-M Ii mice injected with peptide had
 20% CD4 T cells in the lymph nodes when compared
with 1–2% CD4  T cells found in control animals (Fig. 3
Figure 2. (A and B) Development of transgenic cells in TCR-  
C57BL6 mice. TCRTgTCR-   thymocytes were efficiently selected in
the thymus expressing wild-type Ab molecules (A) and repopulate periph-
eral lymphoid organs (B). The insets in (A) and (B) represent the expres-
sion of transgenic V 8 chain on CD4  thymocytes and lymph node cells.
(C–F) The capacity of agonist peptides to induce negative selection of
transgenic thymocytes correlates with their agonist potency. Intraperito-
neal injection of a moderate agonist peptide PCC50V did not induce neg-
ative selection of transgenic thymocytes at a dose of 20  g and induced
only limited deletion at 200  g/mouse (C and E). Injection of the strong
agonist peptide PCC50V54A at 20  g did not induce negative selection
but a dose of 200  g/mouse-induced profound deletion of transgenic thy-
mocytes (D and F). Thymocytes and lymph node cells were stained with
anti-CD4 and anti-CD8 antibodies and analyzed by flow cytometry. Pep-
tides were injected intraperitoneally at 20 or 200  g per mouse and mice
were killed after 24 h. The total number of recovered cells is presented
above each panel. At least three mice were used in each experiment.410 Agonists Induce Positive Selection of CD4  T Cells
C). Newly selected CD4  T cells had normal levels of
TCR and CD4, and the phenotype of naive T cells
(CD44 CD62L ; Fig. 3 G). Also the levels of adhesion
molecules CD2 (LFA-2) and CD11c (LFA-1) were the
same on CD4  lymphocytes from transgenic and peptide-
injected TCRTgTCR-  H2-M Ii  mice (Fig. 3 H). Pep-
tide-selected cells responded to the agonist peptide, though
with much lower potency than CD4  transgenic cells iso-
lated from mice expressing wild-type Ab (Fig. 3 I).
Since the selecting peptide is an agonist, one could argue
that the observed phenomenon results from the expansion
of a small number of peripheral transgenic CD4  T cells
rather than from induced positive selection (24). To test
this possibility, two types of experiments were performed.
In the first experiment, the TCRTgTCR-  H2-M Ii 
mice were thymectomized and then injected with the
PCC50V54A peptide. 2 wk after injection, the mice were
killed and the number of peripheral CD4  T cells was
counted. As shown in Fig. 4 A, the number of CD4 trans-
genic T cells was very low and did not increase in compar-
ison with control mice that were thymectomized, but did
not receive the PCC50V54A peptide. In the second exper-
iment, TCRTgTCR-  H2-M Ii  neonates were injected
with the PCC50V54A peptide and after 24 h thymi from
injected and control neonates were transplanted under the
kidney capsules of H2-M Ii TCR-   mice, which are
devoid of T cells (25). After 10 d, recipient mice were
killed and the presence of transgenic CD4  T cells in the
transplanted thymus and host lymph nodes was determined
by FACS® analysis. As shown in Fig. 4 B, transgenic CD4 
Figure 3. (A–D) The development
of CD4  T cells in TCRTgTCR-
  H2-M Ii  control mice (A) and
mice injected with the selecting pep-
tide PCC50V54A (B–D). Control
TCRTgTCR-  H2-M Ii  mice
were injected with IgGVH peptide
(A). Experimental mice were injected
with 20  g of the PCC50V54A pep-
tide and analyzed after 24 h (B), 48 h
(C), and 14 d (D). Thymocytes (left)
and lymph node cells (right) were
stained with anti-CD4 and anti-CD8
antibodies and analyzed by flow cy-
tometry. Absolute numbers for thy-
mocytes and lymph node cells are
shown above each panel. (E) Injection
of the positively selecting peptide up-
regulated TCR and CD69 expres-
sion on thymocytes. Control mouse
(left) and mouse injected with the se-
lecting peptide (right) were analyzed
by flow cytometry 48 h after peptide
administration. (F) bcl-2 was upregu-
lated in positively selected thy-
mocytes. TCRTgTCR-  H2-M Ii 
mouse was injected intraperitoneally
with 20  g of PCC50V54A peptide
and thymocytes were analyzed after
48 h. Left panel shows thymocyte
staining with CD4 and CD8 anti-
bodies and three gates, based on the
expression of these two surface
markers. Right panel shows bcl-2
expression on gated thymocyte pop-
ulations I–III. Filled histogram
shows staining with isotype-matched
control antibody. (G) Peripheral
lymph node cells that differentiated
in mice injected with the selecting
peptide had naive phenotype. Histo-
grams compare expression of CD44
and CD62L on gated CD4  cells
from TCRTgTCR-   and injected TCRTgTCR-  H2-M Ii  mice. CD44 expression is depicted by (unbroken line) and (broken line) and CD62L ex-
pression by (____ ____) and (-⋅-) for cells isolated from TCRTgTCR-   and injected TCRTgTCR-  H2-M Ii mice, respectively. (H) The expression of
CD2 (LFA-2) and CD11a (LFA-1) was the same on peptide selected CD4  T cells as on cells selected in wild-type TCR transgenic mice. Histograms
compare expression of CD2 and CD11a on gated CD4  cells from TCRTgTCR-   and injected TCRTgTCR-  H2-M Ii  mice. CD2 expression is
depicted by (unbroken line) and (broken line) and CD11a expression by (____  ____) and (-⋅-) for cells isolated from TCRTgTCR-   and injected
TCRTgTCR-  H2-M Ii  mice, respectively. (I) Peripheral lymph node cells that developed in TCRTgTCR-   ( ,  , X) and PCC50V54A in-
jected TCRTgTCR-  H2-M Ii  (  ,  ,  ) mice respond in vitro to the selecting peptide PCC50V54A ( ,  ) or another agonist peptide
PCC50V( ,  ). IgGVH (X,  ) peptide was used as a negative control.411 Kraj et al.
T cells were found only in mice grafted with thymi from
neonates injected with the selecting peptide. Therefore, we
conclude that CD4  T cells appear in the peripheral lymph
nodes of TCRTgTCR-  H2-M Ii  injected with the ag-
onist peptide as a result of positive selection by this peptide.
Antagonist Peptides Do Not Induce Positive or Negative Selec-
tion but Inhibit Positive Selection Induced by Agonist Selecting
Ligands. It has been shown that the peptide component of
the TCR/MHC/peptide complex influences the strength
of interaction between a thymocyte and thymic stromal cell
and hence determines the fate of the thymocyte (26). Mi-
nor alterations in critical amino acid residues that are ex-
posed towards the TCR may have a profound effect on the
outcome of recognition of MHC–peptide complex by the
T cell and change the activation properties of a peptide
ligand from agonist to an antagonist (27). Peptide ligands
positively selecting CD8  thymocytes were initially de-
scribed as having antagonist properties. However, later ex-
periments showed that CD8  thymocytes expressing trans-
genic TCR were selected by peptides with different
activation potencies (28, 29). Similar experiments investi-
gating thymocytes expressing MHC class II–restricted
TCRs in fetal thymic organ cultures (FTOCs), showed that
antagonist peptides either inhibit thymic positive selection
or induce negative selection (30, 31). We have investigated
what is the capacity of antagonist peptides to influence thy-
mic selection using our in vivo model. As shown in Table
I, we have initially found that analogues of PCC(43–58)
with p5 position occupied by E or N have an antagonistic
effect on our transgenic CD4  T cells. Biological proper-
ties of agonist and antagonist peptides were preserved in
both wild-type and H2-M Ii  mice (Fig. 5, A–C). The re-
sponses of transgenic CD4  T cells to agonist peptide
PCC50V54A were reduced by  50% in the presence of
each of these analogues, which is the criteria used to iden-
tify a given peptide as antagonist (27). These antagonist
variants of PCC peptide inhibited the responses of trans-
genic CD4  T cells on APCs derived from wild-type or
H2-M Ii  mice (Fig. 5, B and C). Subsequently, various
doses of PCC50E and PCC50N were tested for their abil-
ity to affect thymic selection in TCRTgTCR-  H2-M Ii 
mice. Regardless of a wide range of administered doses (up
to 50  g), injection of the antagonist peptides did not result
in increased number of CD4  transgenic T cells in the thy-
mus nor induced deletion of CD4 CD8  thymocytes (Fig.
6 A). In conclusion, contrary to the “weak affinity” peptide
ligands that mediate positive selection of CD8  T cells, we
have found that only agonist not antagonist peptides medi-
ate in vivo positive selection of CD4  T cells.
Figure 4. CD4  cells that appear in injected TCRTgTCR-  H2-M Ii 
mice were selected in the thymus. (A) TCRTgTCR-  H2-M Ii  mice
were thymectomized and some mice were injected with the selecting pep-
tide. After 14 d the mice were killed and lymph node cells analyzed by flow
cytometry. Both control (not injected, left) and injected mice (right) had
very few CD4  peripheral T cells. (B) TCRTgTCR-  H2-M Ii  thy-
mocytes are selected by the PCC50V54A peptide in thymic graft recipi-
ents and repopulate peripheral lymph nodes. Thymi from TCRTgTCR-
  H2-M Ii  2-d-old neonates (top) or the same neonates injected with
2  g of the selecting peptide PCC50V54A (bottom) were transplanted
under kidney capsule of the TCR-  H2-M Ii  recipient mice. After 14 d,
recipient mice were killed and cells isolated from transplanted thymic tis-
sue (left) and recipient lymph nodes (right) were stained with anti-CD4
and anti-CD8 antibodies. The absolute number of lymph node cells in
control and experimental recipient animals is shown.
Table I. Peptides Recognized by TCR Transgenic Lymphocytes 
and Their Biological Activities
Peptide Agonist Antagonist
PCC(43–58)  /  
PCC50V54A   
PCC50V   
PCC50L   
PCC 50F   
PCC46A49A50V54A   
PCC 50E   
PCC 50N   
PCC 52Q   
Peptides recognized by transgenic lymphocytes and their biological
activities.412 Agonists Induce Positive Selection of CD4  T Cells
A single thymocyte is likely exposed to numerous differ-
ent peptides bound to MHC and it has been proposed that
the sum of signals produced by these interactions deter-
mines thymocyte fate. It was shown that antagonist pep-
tides can affect thymocyte selection, however these results
were controversial. In one study antagonist peptide inhib-
ited negative selection of thymocytes while in another
study the opposite result was reported (30, 31). In addition,
an antagonist peptide was also described as being capable of
blocking positive selection of CD4  TCR transgenic thy-
mocytes, although it could not be ruled out that this peptide
instead induced late deletion at the stage of single positive
cells (32). To examine how the antagonist peptide affects posi-
tive  selection we coinjected antagonist peptide PCC50E
together with the selecting agonist peptide PCC50V54A at
the same low dose (3  g), and evaluated the outcome of
selection 4 d later. As shown in Fig. 6, B and C the number
of CD4  thymocytes which were positively selected by
PCC50V54A agonist peptide was significantly reduced.
This effect was also reproduced for the second antagonist
peptide PCC50N. It is unlikely that the reduced number of
CD4  thymocytes in mice injected with agonist/antagonist
mixture is a result of late negative selection because a much
higher dose of the same antagonists administered alone did
not induce negative selection of CD4 CD8  thymocytes.
This result argues that a single thymocyte accumulates sig-
nals received by interaction with different MHC–peptide
complexes.
Identification of a Candidate Natural Peptide that Mediates
Positive Selection of TCRTg Thymocytes.  Since the sequence
of the exogenous selecting peptide(s) has been determined,
we hypothesized that the natural selecting ligand exists that
has agonist properties. By testing different PCC analogues
we have determined that amino acids A or F in position 46,
A or T in position 49, A in position 51, and A or N in po-
sition 54 are important for binding to Ab. Moreover, amino
acids V, L, F, I in position 50 were important to stimulate
TCRTg lymphocytes. We have used the peptide motif
(AF)XX(AT)(VLFI)AXX(AN) to search the nonredundant
protein and EST protein databases using different computer
algorithms. These searches resulted in identification of a
mouse proteins which may encode natural peptides with
agonist properties for our TCR. One of these proteins was
the neutral ceramidase that contained amino acid motif
FXXTLYXXA where only Y does not match the original
motif (33). This protein is ubiquitously expressed in many
tissues, including epithelial cells. Subsequently, we synthe-
Figure 5.  (A–C) Peptide agonist and antagonists preserve their properties presented by APCs from wild-type or H2-M Ii  mice. Total lymph node
cells from TCRTgTCR-   mice were stimulated with increasing concentrations of the agonist peptides or control peptide  IgGVH(59–74) presented
by APCs from H2-M Ii  mice (A). Graphs show percentage of inhibition of activation (y axis) with regard to the concentration of the antagonist pep-
tides (x axis, B and C). Wild-type (B) or H2-M Ii  (C) APCs were pulsed with 5  M of agonist peptide PCC50V54A and used to stimulate transgenic
T cells. PCC50E, PCC50N antagonist, and PCC52Q neutral peptide were added at increasing concentrations.
Figure 6. The effect of antag-
onist peptide on thymic selection
of TCRTgTCR-   thymocytes.
Antagonist peptides do not in-
duce negative or positive selec-
tion of transgenic thymocytes.
TCRTgTCR-  H2-M Ii  mice
were injected intraperitoneally
with 50  g of the antagonist
peptide PCC50E (A). Antagonist
peptides inhibit positive selection
induced by an agonist-selecting
ligand (B and C). TCRTgTCR-
  H2-M Ii  mice were injected
intraperitoneally with 3  g of the
agonist peptide PCC50V54A
(B), and mixture of 3  g of agonist peptide PCC50V54A and 3  g of an-
tagonist PCC50E (C). Thymocytes were stained with anti CD4 and CD8
antibodies 48 h after peptide injection. Total thymocyte cell numbers are
shown above each panel.413 Kraj et al.
sized the peptide AGFFQYTLYILASEG which contained
the homologous motif sequence. This peptide when tested
in vitro acted as weak agonist eliciting proliferation of naive
TCRTg CD4  T cells (Fig. 7 A). Injection of 50  g
of neutral ceramidase peptide into TCRTgTCR-  H2-
M Ii  mice resulted in positive selection of transgenic
CD4  thymocytes (Fig. 7 C) and the appearance of CD4 
lymphocytes in the peripheral lymph nodes (Fig. 7 D).
These peripheral CD4  cells weakly proliferated when
stimulated with agonist peptide PCC50V (Fig. 7 B). Hence
using biocomputing analysis we have been able to identify
a candidate natural agonist peptide which after injection
into TCRTgTCR-  H2-M Ii  mice induces positive se-
lection of CD4  T cells. Our results imply that the natural
peptides bound to MHC class II that select thymocytes are
recognized by the relevant TCRs with higher affinity than
have been previously postulated.
Discussion
Many studies have analyzed a role of peptides in positive
selection of MHC class I– and II–restricted T cells. How-
ever, despite great effort these studies have yielded conflict-
ing results on the nature of the positively selecting peptide
ligand. Development of CD8  thymocytes in FTOCs from
 2-microglobulin or transporter associated with antigen
processing 1 knockout mice showed that positive selection
can be peptide specific and that the avidity of the TCR for
the MHC–peptide complex determines the fate of imma-
ture thymocytes (34, 35). The response of CD8  thy-
mocytes selected in FTOCs by altered peptide ligands was
often compromised (10, 11, 36) and none of the selecting
peptides identified in vitro supported positive selection of
the respective transgenic receptor in vivo (37, 38). The se-
lection of CD4  T cells in organ cultures have shown that
peptide agonists either delete or select class II–restricted
TCR transgenic thymocytes towards the CD8  lineage
(39). Peptide antagonists inhibited the generation of CD4 
thymocytes and promoted the selection of CD8  cells or
induced negative selection (30, 31, 40). Positive selection
of CD4 but not CD8  T cells was achieved using either
hybrid monoclonal antibodies or monovalent antibodies
against TCR and CD4 (41, 42). It has been reported that
agonist ligands can induce differentiation of CD4  thymocytes
in reaggregation cultures or in vivo after the intrathymic in-
jection of the recombinant adenovirus encoding the respec-
tive peptide (9, 13, 43). In the latter study agonist, antagonist,
and even peptides with unrelated amino acid sequence
were capable of selecting TCRs with defined antigenic
specificity (9). In contrast, our data strongly suggest that
peptides capable of selecting CD4  T cells may have differ-
ing primary sequence, but they are required to possess ago-
nist activity. Antagonist peptides were not able to induce
positive or negative selection in wide range of tested con-
centrations. In addition, antagonists blocked the activity of
agonists and inhibited positive selection.
The data reported in this paper suggest that positive se-
lection is peptide specific and, in a natural environment,
mediated by agonist peptide ligands. In contrast, analysis of
thymocyte development in mice expressing high density of
Ab–single peptide complexes implied that selection of mul-
tiple TCRs does not require specific peptide (15, 44). Re-
Figure 7. Agonist peptide derived from a mouse natural protein neutral
ceramidase has agonist properties and positively selects transgenic thy-
mocytes when injected into TCRTgTCR-  H2-M Ii  mouse. (A) Total
lymph node cells from TCRTgTCR-   mice were stimulated with in-
creasing concentrations of PCC50V ( ) or neutral ceramidase derived
peptides (X). Unrelated peptide IgGVH(59–74) ( ) was used as a con-
trol. Irradiated splenocytes expressing wild-type Ab were used as
APCs. (B) Sorted peripheral lymph node CD4  cells that developed in
TCRTgTCR-  H2-M Ii  mice injected with PCC50V54A ( ) or
neutral ceramidase peptide ( ) respond in vitro to the agonist peptide
PCC50V. IgGVH peptide was used as a negative control for the response
of CD4   cells from TCRTgTCR-  H2-M Ii  mice injected with
PCC50V54A ( ) or neutral ceramidase peptides (X). Irradiated spleno-
cytes from H2-M Ii  mice were used as APCs. (C) Neutral ceramidase
peptide mediates positive selection of transgenic CD4  thymocytes in
TCRTgTCR-  H2-M Ii  mice. TCRTgTCR-  H2-M Ii  mice were
injected intraperitoneally with 50  g of the IgGVH (left) and neutral cer-
amidase (right) peptide. The percentage of CD4  single positive cells was
0.7   0.4 and 1.8   0.6 in control and experimental mice 3 d after pep-
tide injection. (D) Positively selected thymocytes repopulated peripheral
lymph nodes. Lymph node cells from TCRTgTCR-  H2-M Ii  mice
were injected with IgGVH (left) and neutral ceramidase (right) peptide and
analyzed 12 d later. The percentage of CD4  positive cells was 2.4   0.8
and 7.6   1.8 in control and experimental mice, respectively.414 Agonists Induce Positive Selection of CD4  T Cells
sults obtained in both experimental models are consistent
with the avidity model of positive selection which postu-
lates that a T cell might be positively selected by multiple
low affinity or few high affinity MHC–peptide complexes
(6). The CD4  T cells found in mice expressing single
AbEp complex had TCRs with undetectable affinity to
AbEp (to avoid negative selection), in contrast to transgenic
CD4  T cells described in this paper that are positively se-
lected by few high affinity (agonist) Ab–peptide complexes.
An alternative explanation of T cell selection in mice ex-
pressing Ab–single peptide complex postulated that most
CD4  lymphocytes are selected on contaminating, low
abundance peptides (45) which is consistent with the re-
ported here positive selection by agonist peptides. The on-
going studies on the complexity of peptides present in mice
expressing various covalent MHC class II–peptide com-
plexes in vivo should soon reveal how CD4  T cells de-
velop in these mice.
One of the intriguing phenomenons we have observed is
the decreased proliferation of peptide selected CD4  T cells
after TCR stimulation. This effect is not peptide specific
since the same cells respond poorly to anti-CD3 antibody
stimulation and does not reflect lower expression of the
TCR or costimulatory molecules (unpublished data). The
discussed feature is also not a characteristic of our experi-
mental system. Cells expressing the same transgenic TCR
are very efficiently selected on endogenous peptides present
in Ii  mice and have similarly decreased response to TCR
stimulation (data not shown). We are currently investigat-
ing if this phenomenon is caused by lower MHC class II
expression in H2-M Ii  or Ii  mice, the lack of the select-
ing peptide ligand in the periphery, decreased life span, or
inherently elevated activation threshold due to the nature
of the selecting peptide ligand.
Because     TCRs expressed on CD4 CD8  thymo-
cytes likely interact with multiple MHC–peptide complexes,
the fate of a thymocyte may depend on the net result of all
these interactions (32, 46). Experiments described in this re-
port, where coinjected antagonist peptide inhibited positive
selection support this hypothesis and raise interesting ques-
tions about how the balance of agonist and antagonist
ligands impacts T cell development. The doses of selecting
agonist and antagonist peptides were chosen to be low to
exclude the possibility that the observed phenomenon is
due to competition for Ab binding. Instead, the unique sig-
nal induced by both agonist and antagonist could result in
the inhibition of positive selection. Since the transition
from CD4 CD8  to CD4  thymocytes requires 24–48 h
experiments where injection of the antagonist peptide is de-
layed or proceeds the injection of agonist peptide may de-
termine the course of events that lead to inhibition of posi-
tive selection by antagonist MHC–peptide ligand.
Recent experiments in reaggregation cultures raised the
possibility that bone marrow dendritic cells deliver a strong
agonist signal necessary to induce CD4  T cell differentia-
tion (47). We have investigated the development of trans-
genic CD4  T cells in chimeras made by reconstituting
H2-M Ii  mice with the bone marrow from TCRTg
TCR-    mice (TCRTgTCR-  →H2-M Ii  chimeras).
The development of thymocytes in such chimeras is arrested
at the CD4 CD8  stage despite the presence of selecting
wild-type Ab–self-peptide complexes on bone marrow–
derived dendritic cells. Mature CD4  T cells appeared only
after injection of the selecting peptide PCC50V54A (data
not shown). This suggest that in our in vivo model, in con-
trast to the reaggregation cultures (47), radioresistant thy-
mic epithelial cells are required to provide an agonist signal
that induces thymocyte differentiation towards CD4  lin-
eage in vivo.
We have induced positive selection of transgenic thy-
mocytes using a peptide dose that did not delete these cells
in wild-type mice. The presentation of injected agonist
peptides by wild-type Ab molecules present on bone mar-
row cells in TCRTgTCR-  →H2-M Ii  radiation chi-
meras also did not induce negative selection (data not
shown). One could then postulate that agonist peptides dif-
fer in their relative capacity to induce positive versus nega-
tive selection. Some of these peptides induce negative se-
lection even at a very low dose, but others induce positive
selection at a low dose and negative selection only when
used at a high dose. Under physiological conditions, it is
likely that positively selecting peptides are presented at very
low concentration so it seems plausible that these peptides
would have agonist activity. Peptide-specific positive selec-
tion would favor interaction with a narrow range of more
potent agonists while positive selection of more promiscu-
ous TCRs may involve collective interaction with a
broader range of peptides sharing lower agonist potency
(16, 48). Alternatively, selection of CD4  T cells was pos-
sible in our system because the positively selecting agonist
ligand sets the threshold for negative selection, and nega-
tive selection requires an interaction with the more potent
agonist ligand (49, 50). Signaling studies also support the
notion that agonist peptides may be natural ligands for se-
lection of the class II–restricted thymocytes (51, 52), based
on the observation that commitment to the CD4 lineage
requires a stronger signal via TCR than commitment to-
wards the CD8 lineage. Previously published reports de-
scribing natural peptides capable of selecting     TCR
transgenic T cells used mass spectroscopy analysis to iden-
tify peptides eluted from MHC molecules (28, 29). The
advantage of this method is that it identifies peptides physi-
cally bound to MHC, but because of limited sensitivity of
detection this analysis may be biased in favor of the most
abundant peptides. Here, we have attempted to use an al-
ternative method to find peptides that may be the natural
selecting ligands. We have searched protein database for the
presence of a sequence motif that we identified present in
agonist selecting peptides. A peptide fragment derived from
the identified protein had both agonist properties and posi-
tively selected transgenic thymocytes. Although, this
method does not guarantee that this particular peptide is
presented in the thymus, the expression pattern of neutral
ceramidase suggests that this is a good candidate protein to415 Kraj et al.
yield selecting peptides (33, 53). Our approach may be-
come even more useful in the future as more sequences are
available in the databases.
Mice transgenic for MHC class II–restricted    TCR
and lacking H2-M and Ii molecules likely constitute a non-
selecting environment for most of MHC class II–restricted
transgenic receptors studied so far. We show, for the first
time, that in vivo administration of soluble peptide may re-
store positive selection of CD4  thymocytes in such mice.
This strategy may be used to identify and determine the
properties of peptides capable of selecting TCR transgenic
CD4  T cells with different antigen specificities in vivo.
Since in this experimental model, the onset of positive se-
lection of a large number of thymocytes is known, it may
be particularly useful for analysis of gene expression pat-
terns associated with positive selection and lineage commit-
ment of CD4  thymocytes within hours after the delivery
of the positively selecting signal. Furthermore, in this study
we have identified a number of selecting and nonselecting
peptides so it will be possible, using soluble recombinant
proteins, to determine the relationship between the affinity
of the TCR for different peptide–MHC class II complexes
and the capacity to induce positive selection in vivo. Our
finding challenges the existing dogma that low-affinity
peptides are predisposed to induce positive selection while
high-affinity ligands only induce negative selection. In-
stead, for CD4  T cells the latter not the former peptides
seem to be predisposed to induce positive selection.
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